SCHEMBL22470132

SCHEMBL22470132

CC1(CNC2(c3ccc(F)c(C(F)(F)F)c3)CC2)CCCN1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 5/20 0.42
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
MCHR1 Q99705 1/20 0.36
SLC6A9 P48067 2/20 0.36
PDE2A O00408 7/20 0.36
NOTUM Q6P988 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
TAS1R2 Q8TE23 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22470464 1.00 KCNN4 (0.42) KCNN4HDAC3HDAC1HDAC2HDAC6
SCHEMBL22470129 1.00 KCNN4 (0.42) KCNN4HDAC3HDAC1HDAC2HDAC6
SCHEMBL28649872 0.87 KCNN4 (0.41) KCNN4HDAC3HDAC1HDAC2HDAC6
SCHEMBL28649915 0.87 KCNN4 (0.41) KCNN4HDAC3HDAC1HDAC2HDAC6
SCHEMBL28649871 0.87 KCNN4 (0.41) KCNN4HDAC3HDAC1HDAC2HDAC6
SCHEMBL30916773 0.77 KCNN4 (0.61) KCNN4MCHR1SLC6A9NOTUM
SCHEMBL22470149 0.77 KCNN4 (0.61) KCNN4MCHR1SLC6A9NOTUM
SCHEMBL22470153 0.77 KCNN4 (0.61) KCNN4MCHR1SLC6A9NOTUM
SCHEMBL22470146 0.77 KCNN4 (0.61) KCNN4MCHR1SLC6A9NOTUM
SCHEMBL22470455 0.76 KCNN4 (0.42) KCNN4HDAC3HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12006289-B2 Potassium channel inhibitors SANIONA A/S (DK) 2024-06-11 US disclosed
CN-113631538-B Novel potassium channel inhibitors 萨尼奥纳有限责任公司 2024-05-31 CN disclosed
US-20220169602-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2022-06-02 US disclosed
EP-3941903-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Saniona A/S (DK) 2022-01-26 EP disclosed
WO-2020193419-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2020-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169602-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 KCNN4 57/4885HDAC3 280/4885HDAC1 703/4885
US-12006289-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 KCNN4 48/4885HDAC3 277/4885HDAC1 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.